HBK Investments’s AstraZeneca AZN Stock Holding History

HBK Investments’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-237,500	Closed	-$23.6M	–	831
2021 Q1	$23.6M	Buy	237,500 +162,500	+217%	+$16.3M	0.11%	60
2020 Q4	$7.5M	Buy	+75,000	New	+$7.94M	0.05%	190

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

HBK Investments's AZN Position: Q2 2019 in Review

HBK Investments sold out of AstraZeneca (AZN) in Q2 2019, closing a stake of 104,911 shares — an estimated $8.48M sold.

HBK Investments first reported a position in AZN in Q2 2013 and held it in 8 quarters. The position peaked at $8.48M in Q1 2019. 546 funds tracked by Wall St. Rank hold AZN as of Q2 2019.

HBK Investments reported no remaining AstraZeneca position as of Q2 2019 after selling out during the quarter.
HBK Investments sold 104,911 AstraZeneca shares in Q2 2019, an estimated $8.48M.
HBK Investments first reported a position in AstraZeneca in Q2 2013 and held it in 8 quarters.
HBK Investments's AstraZeneca position peaked at $8.48M in Q1 2019.
546 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2019.

Based on HBK Investments's 13F filing for Q2 2019, filed 14 Aug 2019.